ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
MEI Pharma, KHK to develop and commercialize ME-401
biospectrumasia
November 26, 2018MEI Pharma, Inc. and Kyowa Hakko Kirin Co., Ltd. (KHK), have announced the execution of a license agreement granting KHK exclusive rights to develop and commercialize ME-401 in Japan. -
MEI Pharma, BeiGene Collaborate on ME-401, Zanubrutinib Combination
americanpharmaceuticalreview
October 12, 2018MEI Pharma and BeiGene announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of pati
Pharma Sources Insight January 2025
